These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34918639)

  • 1. The efficacy and safety of different bismuth agents in Helicobacter pylori first-line eradication: A multicenter, randomized, controlled clinical trial.
    Cao Y; Zhang J; Liu Y; Zhang L; Wang L; Wang J; Qi Y; Lv H; Liu J; Huo L; Wei X; Shi Y
    Medicine (Baltimore); 2021 Dec; 100(50):e27923. PubMed ID: 34918639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colloidal bismuth pectin-containing quadruple therapy as the first-line treatment of Helicobacter pylori infection: A multicenter, randomized, double-blind, non-inferiority clinical trial.
    Xie Y; Hu Y; Zhu Y; Wang H; Wang QZ; Li YQ; Wang JB; Zhang ZY; Zhang DK; Liu XW; Lu NH
    Helicobacter; 2023 Jun; 28(3):e12978. PubMed ID: 37002653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
    Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
    Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of high-dose esomeprazole-amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial.
    Bi H; Chen X; Chen Y; Zhao X; Wang S; Wang J; Lyu T; Han S; Lin T; Li M; Yuan D; Liu J; Shi Y
    Chin Med J (Engl); 2022 Jul; 135(14):1707-1715. PubMed ID: 36193978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China.
    Xie Y; Zhu Z; Wang J; Zhang L; Zhang Z; Lu H; Zeng Z; Chen S; Liu D; Lv N;
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of 10 and 14 days of antofloxacin-based versus 14 days of clarithromycin-based bismuth quadruple therapy for Helicobacter pylori eradication: A randomized trial.
    He XJ; Wang XL; Huang XY; Li DZ; Liu G; Wang W; Li DL
    Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102052. PubMed ID: 36400418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial.
    Zhang D; Ke L; Ni Z; Chen Y; Zhang LH; Zhu SH; Li CJ; Shang L; Liang J; Shi YQ
    Medicine (Baltimore); 2017 Aug; 96(32):e7697. PubMed ID: 28796053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
    Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ
    BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing high-dose dual therapy with bismuth-containing quadruple therapy for the initial eradication of Helicobacter pylori infection on Hainan Island: A randomized, multicenter clinical trial.
    Liu DN; Wang QY; Li PY; Wu DH; Pan J; Chen ZY; Li YQ; Han XY; Lan C; Tang J; Tan Y; Mo CY; Yang WZ; Han JL; Huang XX
    Clin Res Hepatol Gastroenterol; 2023 May; 47(5):102125. PubMed ID: 37062356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of high-dose dual therapy with bismuth-containing quadruple therapy in Helicobacter pylori-infected treatment-naive patients: An open-label, multicenter, randomized controlled trial.
    Guan JL; Hu YL; An P; He Q; Long H; Zhou L; Chen ZF; Xiong JG; Wu SS; Ding XW; Luo HS; Li PY
    Pharmacotherapy; 2022 Mar; 42(3):224-232. PubMed ID: 35075679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy comparison of 7- and 14-day P-CAB based bismuth-containing quadruple regimen with PPI based bismuth-containing quadruple regimen for Helicobacter pylori infection: rationale and design of an open-label, multicenter, randomized controlled trial.
    Oh CK; Lim H; Seo SI; Lee SP; Bang CS; Shin WG; Kim JB; Jang HJ; Baik GH
    BMC Gastroenterol; 2023 Dec; 23(1):453. PubMed ID: 38129806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The Efficacy of Bismuth-containing Quadruple Therapy after Moxifloxacin-based Sequential Therapy Failure in Helicobacter pylori Eradication].
    Kwon S; Lee DH; Kang JB; Kim N; Park YS; Shin CM; Yoon H; Choi YJ
    Korean J Gastroenterol; 2018 Apr; 71(4):196-203. PubMed ID: 29684968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antofloxacin-based bismuth quadruple therapy is safe and effective in Helicobacter pylori eradication: A prospective, open-label, randomized trial.
    He XJ; Zeng XP; Jiang CS; Liu G; Li DZ; Wang W
    Arab J Gastroenterol; 2021 Mar; 22(1):47-51. PubMed ID: 33551347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A multicenter randomized controlled study of bismuth-containing quadruple therapy followed by Jing-Hua-Wei-Kang in the treatment of patients newly diagnosed with
    Ma PP; Meng LN; Wang MT; Jin HF; Fan YH; Zha AS; Huo XH; Chen DF; Cao ZQ; Tang XF; Yang P; Shi ZH; Li TW; Meng J; Gan C; Chen GX; Sha WH; Du Q; Li Y; Lyu B
    Zhonghua Yi Xue Za Zhi; 2021 Jul; 101(26):2060-2065. PubMed ID: 34275239
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial.
    Chen S; Shen W; Liu Y; Dong Q; Shi Y
    Chin Med J (Engl); 2023 Jul; 136(14):1690-1698. PubMed ID: 37469024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
    Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
    Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ten-day Sequential Therapy versus Bismuth Based Quadruple Therapy as Second Line Treatment for Helicobacter pylori Infection].
    Kim SB; Lee SH; Kim KO; Jang BI; Kim TN
    Korean J Gastroenterol; 2015 Nov; 66(5):261-7. PubMed ID: 26586348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for
    Bang CS; Lim H; Jeong HM; Shin WG; Choi JH; Soh JS; Kang HS; Yang YJ; Hong JT; Shin SP; Suk KT; Lee JJ; Baik GH; Kim DJ
    Gut Microbes; 2020 Sep; 11(5):1314-1323. PubMed ID: 32362221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of bismuth quadruple regimens containing tetracycline or furazolidone for initial eradication of Helicobacter pylori.
    Wang J; Cao Y; He W; Li X
    Medicine (Baltimore); 2021 Dec; 100(51):e28323. PubMed ID: 34941132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial.
    Su J; Zhou X; Chen H; Hao B; Zhang W; Zhang G
    Medicine (Baltimore); 2017 Feb; 96(7):e5859. PubMed ID: 28207505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.